Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 6/2014

01-08-2014 | Research Paper

COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib

Authors: Emma Bell, Frida Ponthan, Claire Whitworth, Deborah A. Tweddle, John Lunec, Christopher P. F. Redfern

Published in: Clinical & Experimental Metastasis | Issue 6/2014

Login to get access

Abstract

COX2 is an inducible cyclooxygenase implicated in the metastasis and migration of tumour cells. In neuroblastoma, COX2 expression has been detected in both cell lines and tumours. The treatment of neuroblastoma cells in vitro with celecoxib, a COX2 inhibitor, induces apoptosis. The aim of this study was to investigate the role of COX2 in neuroblastoma tumour biology by creating a cell line in which COX2 could be conditionally expressed. Xenograft studies showed that the conditional expression of COX2 enhanced tumour growth and malignancy. Elevated COX2 expression enhanced the proliferation and migration of neuroblastoma cells in vitro. However, elevated COX2 expression or variation between cell lines did not affect sensitivity to the COX2 inhibitor celecoxib, indicating that celecoxib does not promote cell death through COX2 inhibition. These data show that increased COX2 expression alone can enhance the tumorigenic properties of neuroblastoma cells; however, high levels of COX2 may not be a valid biomarker of sensitivity to non-steroidal anti-inflammatory drugs such as celecoxib.
Literature
1.
Gasparini G et al (2003) Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 4(10):605–615PubMedCrossRef
2.
Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145–182PubMedCrossRef
3.
Singh B et al (2005) COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 26(5):1393–1399PubMed
4.
Singh B et al (2007) COX-2 involvement in breast cancer metastasis to bone. Oncogene 26(26):3789–3796PubMedCrossRef
5.
6.
Gupta GP et al (2007) Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446(7137):765–770PubMedCrossRef
7.
Ren R et al (2007) Gene expression profiles identify a role for cyclooxygenase 2-dependent prostanoid generation in BMP6-induced angiogenic responses. Blood 109(7):2847–2853PubMedCentralPubMed
8.
Rodriguez C et al (2008) COX2 expression and Erk1/Erk2 activity mediate Cot-induced cell migration. Cell Signal 20(9):1625–1631PubMedCrossRef
9.
Wu G et al (2006) Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res 69(2):512–519PubMedCrossRef
10.
Johnsen JI et al (2004) Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 64(20):7210–7215PubMedCrossRef
11.
Ara T et al (2009) Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 69(1):329–337PubMedCentralPubMedCrossRef
12.
Rasmuson A et al (2012) Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS One 7(1):e29331PubMedCentralPubMedCrossRef
13.
14.
Ponthan F et al (2007) Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 13(3):1036–1044PubMedCrossRef
15.
16.
Biedler JL et al (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38(11 Pt 1):3751–3757PubMed
17.
Biedler JL, Spengler BA (1976) Metaphase chromosome anomaly: association with drug resistance and cell-specific products. Science 191(4223):185–187PubMedCrossRef
18.
Schleiermacher G et al (2003) Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. Cancer Genet Cytogenet 141(1):32–42PubMedCrossRef
19.
Brodeur GM, Sekhon G, Goldstein MN (1977) Chromosomal aberrations in human neuroblastomas. Cancer 40(5):2256–2263PubMedCrossRef
20.
Lovat PE et al (2002) GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of neuroblastoma. Cancer Res 62(18):5158–5167PubMed
21.
Demaison C et al (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13(7):803–813PubMedCrossRef
22.
Bell E et al (2006) The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage. Cell Cycle 5(22):2639–2647PubMedCrossRef
23.
Scudiero DA et al (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48(17):4827–4833PubMed
24.
Team R (2008) Language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
25.
Pinheiro J, Bates, D, DebRoy, S, Sarkar, D, R Core Team (2008) nlme: linear and non linear mixed effects models. R package version 3, pp 1–89
26.
Pham DH et al (2008) Attenuation of leakiness in doxycycline-inducible expression via incorporation of 3′ AU-rich mRNA destabilizing elements. Biotechniques 45(2):155–162PubMedCrossRef
27.
Sartelet H et al (2012) Description of a new xenograft model of metastatic neuroblastoma using NOD/SCID/Il2rg null (NSG) mice. In vivo 26(1):19–29PubMed
28.
Zhu J et al (2004) From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 64(12):4309–4318PubMedCrossRef
29.
Ding H et al (2008) OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis. Int J Cancer 123(12):2923–2930PubMed
30.
Schonthal AH (2007) Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Brit J Cancer 97(11):1465–1468PubMedCentralPubMedCrossRef
31.
Metadata
Title
COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib
Authors
Emma Bell
Frida Ponthan
Claire Whitworth
Deborah A. Tweddle
John Lunec
Christopher P. F. Redfern
Publication date
01-08-2014
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 6/2014
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-014-9656-3

Other articles of this Issue 6/2014

Clinical & Experimental Metastasis 6/2014 Go to the issue

Research Paper

Metadherin expression and lung relapse in patients with colorectal carcinoma

Research Paper

Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on αv integrins

Review

Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs

Research Paper

Hyaluronan expression as a significant prognostic factor in patients with malignant peripheral nerve sheath tumors

Research Paper

ADRM1 gene amplification is a candidate driver for metastatic gastric cancers

Research Paper

Living in shear: platelets protect cancer cells from shear induced damage
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits